Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort
PER demonstrated clinically meaningful efficacy and acceptable safety in refractory focal epilepsy, with sustained response rates and seizure freedom over 12 months. Male gender, higher doses, and late add-on use predicted better outcomes, while adults experienced fewer adverse events. These real-world findings support PER's role in treatment-resistant cases.
Authors
- Lu-wen Huang
- Wei Peng
- Ting Zhang (ORCID: https://orcid.org/0000-0003-4892-8281)
- Jinmei Li (ORCID: https://orcid.org/0000-0002-7411-8269)
- Tong Yi
- Xiaohui Lai
- Dong Zhou
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Suizhou Central Hospital (CN)
- Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
Publication Details
- Journal
- Brain and Behavior
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1002/brb3.70968
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00